A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
NPPA has capped the trade margin for Oxygen Concentrators at 70% on Price to Distributor (PTD) level
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
The company has decided to transfer our rights in relation to the lodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
Subscribe To Our Newsletter & Stay Updated
